NEW YORK (GenomeWeb) – Roka Bioscience said after the close of the market on Thursday that its revenues for the second quarter increased 7 percent year over year as it missed the consensus Wall Street estimate on the top and bottom lines. 

The foodborne pathogen molecular diagnostics firm said that for the three months ended June 30, it recorded $1.5 million in revenues, up from $1.4 million in Q2 2014. It fell short of the analysts' average estimate of $1.6 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.